Introduksjon
Denne siden gir en grundig analyse av den kjente historikken for insidernes handelsaktiviteter for Schuth Alexander O.. Insidere er ledere, direktører eller betydelige investorer i et selskap. Det er ulovlig for insidere å gjøre handler i deres selskaper basert på spesifikke, ikke-offentlig informasjon. Dette betyr ikke at det er ulovlig for dem å gjøre noen handler i deres egne selskaper. Imidlertid må de rapportere alle handler til SEC via et skjema 4. Til tross for disse begrensningene, antyder akademisk forskning at insidere - generelt sett - har en tendens til å overgå markedet i sine egne selskaper.
Gjennomsnittlig handelslønnsomhet
Den gjennomsnittlige handelslønnsomheten er den gjennomsnittlige avkastningen av alle åpne markedskjøp gjort av insideren de siste tre årene. For å beregne dette, undersøker vi hvert eneste åpne marked, uplanlagte kjøp som er gjort av insideren, men dette inkluderer ikke alle handler som ble markert som en del av en 10b5-1 handelsplan. Vi beregner deretter gjennomsnittlig ytelse av disse handlene over 3, 6 og 12 måneder, gjennomsnittlig hver av disse varighetene for å generere en endelig ytelsesmåling for hver handel. Til slutt,
Dersom lønnsomheten for denne interne handelen er "N/A", har enten den interne personen ikke gjort noen åpen-markeds kjøp de siste tre årene, eller så er handlene for nylig til å beregne en pålitelig prestasjonsmåler.
Oppdateringsfrekvens: Daglig
Selskaper med rapporterte insiderposisjoner
SEC-arkiveringene indikerer at Schuth Alexander O. har rapporterte beholdninger av handler i følgende selskaper:
Verdipapir | Navn | Siste rapporterte høydepunkter |
---|---|---|
US:DNLI / Denali Therapeutics Inc. | COFO and Secretary | 242 346 |
Hvordan tolke diagrammene
De følgende diagrammene viser aksjens ytelse etter hver åpen markedstransaksjon som ikke var planlagt, utført av Schuth Alexander O.. Ikke-planlagte handler er handler som ikke ble gjort som en del av en 10b5-1 handelsplan. Aksjeytelsen er kartlagt som kumulativ prosentendring i aksjekursen. For eksempel, hvis en innsidehandel ble gjort 1. januar 2019, vil diagrammet vise daglig prosentendring for verdipapiret til dagens dato. Dersom aksjeprisen går fra $10 til $15 i løpet av denne tiden, vil den kumulative prosentendringen i aksjeprisen være 50%. En endring i prisen fra $10 til $20 vil være 100%, og en endring i prisen fra $10 til $5 vil være - 50%.
Til syvende og sist er målet vårt å avgjøre hvor tett insidernes handler korrelerer med overavkastninger (positiv eller negativ) i aksjekursen for å se om insidere timer sine handler for å tjene på intern informasjon. Se for deg en situasjon der en insider gjør dette. I denne situasjonen, forventer vi enten (a) positive avkastninger etter kjøp, eller (b) negative avkastninger etter salg. I tilfelle (a) KJØP-diagrammet ville vise en serie av oppadgående kurver, som indikerer positive avkastninger etter hver kjøpstransaksjon. I tilfelle (b) ville SALG-diagrammet vise en serie av nedadgående kurver, som indikerer negative avkastninger etter hver salgstransaksjon.
Imidlertid er dette alene ikke nok til å dra konklusjoner. Hvis, for eksempel, aksjeprisen for selskapet steg jevnt over mange år uten å følge en syklisk trend, ville vi forventet at alle postkjøpsdiagrammer skal ha en stigende trend. På samme måte vil ikke-sykliske nedganger over mange år resultere i nedadgående trend i post-trade diagrammer. Ingen av disse diagrammene ville antyde aktiviteter som insidertrening.
Den sterkeste indikatoren ville vært en situasjon der aksjekursen var ekstremt syklisk, og det var både positive signaler i KJØPSdiagrammet og negative plot i SALGSdiagrammet. Denne situasjonen ville vært sterkt antydende om en insider som timet handler til sin økonomiske fordel.
Innsidernes handelshistorikk
Tabellen viser den komplette listen over innsidehandler gjort av Schuth Alexander O. som avslørt til Securies Exchange Comission (SEC).
Fildato | Transaksjonsdato | Skjema | Ticker | Verdipapir | Kode | Aksjer | Gjenværende aksjer | Prosent endring |
Aksje pris |
Transaksjons verdi |
Gjenværende verdi |
|
---|---|---|---|---|---|---|---|---|---|---|---|---|
2025-08-14 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | −2 937 | 242 346 | −1,20 | 13,58 | −39 884 | 3 291 059 | |
2025-01-08 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | −2 907 | 244 308 | −1,18 | 20,81 | −60 495 | 5 084 049 | |
2025-01-08 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | −12 255 | 247 215 | −4,72 | 20,22 | −247 796 | 4 998 687 | |
2025-01-07 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
A - Award | 54 180 | 259 470 | 26,39 | ||||
2024-12-31 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
M - Exercise | 6 708 | 205 290 | 3,38 | 5,28 | 35 418 | 1 083 931 | |
2024-11-26 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
M - Exercise | 20 516 | 198 582 | 11,52 | 0,68 | 13 951 | 135 036 | |
2024-11-12 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −300 | 178 066 | −0,17 | 31,29 | −9 387 | 5 571 685 |
2024-11-12 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −2 925 | 178 366 | −1,61 | 30,72 | −89 856 | 5 479 404 |
2024-11-12 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −12 333 | 181 291 | −6,37 | 29,68 | −366 043 | 5 380 717 |
2024-11-12 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
M - Exercise | 15 558 | 193 624 | 8,74 | 5,28 | 82 146 | 1 022 335 | |
2024-08-22 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −2 547 | 178 066 | −1,41 | 24,78 | −63 115 | 4 412 475 |
2024-08-22 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −3 353 | 180 613 | −1,82 | 23,54 | −78 930 | 4 251 630 |
2024-08-22 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | −2 453 | 183 966 | −1,32 | 23,79 | −58 357 | 4 376 551 | |
2024-08-15 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | −2 272 | 186 419 | −1,20 | 22,89 | −52 006 | 4 267 131 | |
2024-02-15 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −20 128 | 187 341 | −9,70 | 17,66 | −355 460 | 3 308 442 |
2024-02-15 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | −2 716 | 207 469 | −1,29 | 17,29 | −46 960 | 3 587 139 | |
2024-02-12 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
M - Exercise | 50 000 | 210 185 | 31,21 | 0,68 | 34 000 | 142 926 | |
2024-01-09 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | −9 972 | 539 307 | −1,82 | 19,43 | −193 756 | 10 478 735 | |
2024-01-05 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
A - Award | 53 720 | 170 157 | 46,14 | ||||
2023-08-25 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −2 522 | 518 989 | −0,48 | 23,17 | −58 435 | 12 024 975 |
2023-08-23 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | −2 478 | 521 511 | −0,47 | 22,59 | −55 978 | 11 780 933 | |
2023-08-16 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −2 772 | 518 989 | −0,53 | 23,67 | −65 613 | 12 284 470 |
2023-08-14 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | −2 853 | 521 761 | −0,54 | 24,18 | −68 986 | 12 616 181 | |
2023-07-19 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −9 702 | 518 989 | −1,84 | 30,01 | −291 157 | 15 574 860 |
2023-07-19 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −10 000 | 528 691 | −1,86 | 29,60 | −296 000 | 15 649 254 |
2023-07-19 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
M - Exercise | 10 000 | 538 691 | 1,89 | 5,28 | 52 800 | 2 844 288 | |
2023-05-17 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −800 | 528 691 | −0,15 | 29,23 | −23 384 | 15 453 638 |
2023-05-17 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −9 200 | 529 491 | −1,71 | 28,55 | −262 660 | 15 116 968 |
2023-05-17 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
M - Exercise | 10 000 | 538 691 | 1,89 | 5,28 | 52 800 | 2 844 288 | |
2023-04-14 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −4 898 | 528 691 | −0,92 | 25,04 | −122 646 | 13 238 423 |
2023-04-14 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
M - Exercise | 4 898 | 533 589 | 0,93 | 5,28 | 25 861 | 2 817 350 | |
2023-04-14 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −5 102 | 528 691 | −0,96 | 25,04 | −127 754 | 13 238 423 |
2023-04-14 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
M - Exercise | 5 102 | 533 793 | 0,97 | 5,28 | 26 939 | 2 818 427 | |
2023-02-15 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | −3 497 | 528 691 | −0,66 | 30,09 | −105 225 | 15 908 312 | |
2023-02-15 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
M - Exercise | 25 000 | 524 902 | 5,00 | 0,68 | 17 000 | 356 933 | |
2023-02-10 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | −1 521 | 499 902 | −0,30 | 30,89 | −46 984 | 15 441 973 | |
2023-01-19 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −114 | 497 173 | −0,02 | 29,87 | −3 405 | 14 850 558 |
2023-01-19 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −9 886 | 497 287 | −1,95 | 29,53 | −291 934 | 14 684 885 |
2023-01-19 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
M - Exercise | 10 000 | 507 173 | 2,01 | 5,28 | 52 800 | 2 677 873 | |
2023-01-09 |
|
4/A | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | −2 912 | 492 309 | −0,59 | 28,70 | −83 574 | 14 129 268 | |
2023-01-09 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | −2 636 | 497 173 | −0,53 | 28,44 | −74 968 | 14 139 600 | |
2023-01-05 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | −2 912 | 149 828 | −1,91 | 28,70 | −83 574 | 4 300 064 | |
2023-01-05 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
A - Award | 41 120 | 157 578 | 35,31 | ||||
2022-10-12 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
M - Exercise | 20 000 | 487 471 | 4,28 | 0,68 | 13 600 | 331 480 | |
2022-08-23 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | −2 576 | 467 471 | −0,55 | 33,22 | −85 575 | 15 529 387 | |
2022-08-11 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
A - Award | 22 500 | 121 458 | 22,74 | ||||
2022-02-15 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | −2 803 | 465 047 | −0,60 | 34,68 | −97 208 | 16 127 830 | |
2022-02-11 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | −1 423 | 460 564 | −0,31 | 37,10 | −52 800 | 17 088 997 | |
2022-01-07 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | −2 846 | 457 737 | −0,62 | 44,77 | −127 415 | 20 492 885 | |
2022-01-05 |
|
4 | DNLI |
Denali Therapeutics Inc.
Stock Option (right to buy) |
A - Award | 93 000 | 93 000 | |||||
2022-01-05 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
A - Award | 31 000 | 117 454 | 35,86 | ||||
2021-12-08 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −7 200 | 453 083 | −1,56 | 42,45 | −305 640 | 19 233 373 |
2021-12-08 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −2 800 | 460 283 | −0,60 | 41,82 | −117 096 | 19 249 035 |
2021-11-08 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −3 283 | 463 083 | −0,70 | 53,23 | −174 754 | 24 649 908 |
2021-11-08 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −6 717 | 466 366 | −1,42 | 52,65 | −353 650 | 24 554 170 |
2021-10-06 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −4 006 | 473 083 | −0,84 | 51,04 | −204 466 | 24 146 156 |
2021-10-06 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −5 994 | 477 089 | −1,24 | 50,24 | −301 139 | 23 968 951 |
2021-09-22 |
|
4 | DNLI |
Denali Therapeutics Inc.
Stock Option (right to buy) |
M - Exercise | −9 045 | 240 078 | −3,63 | ||||
2021-09-22 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
M - Exercise | 9 045 | 95 499 | 10,46 | 0,68 | 6 151 | 64 939 | |
2021-09-09 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −2 441 | 474 038 | −0,51 | 56,05 | −136 818 | 26 569 830 |
2021-09-09 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −5 350 | 476 479 | −1,11 | 55,67 | −297 834 | 26 525 586 |
2021-09-09 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −2 209 | 481 829 | −0,46 | 54,70 | −120 832 | 26 356 046 |
2021-08-23 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | −196 | 484 038 | −0,04 | 50,10 | −9 820 | 24 250 304 | |
2021-08-23 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | −2 348 | 484 234 | −0,48 | 49,56 | −116 367 | 23 998 637 | |
2021-08-06 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −200 | 481 582 | −0,04 | 52,99 | −10 598 | 25 519 030 |
2021-08-06 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −8 236 | 481 782 | −1,68 | 52,34 | −431 064 | 25 215 988 |
2021-08-06 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −1 564 | 490 018 | −0,32 | 51,52 | −80 571 | 25 243 767 |
2021-07-08 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −10 000 | 491 582 | −1,99 | 76,20 | −762 040 | 37 460 515 |
2021-06-08 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −4 340 | 501 582 | −0,86 | 64,82 | −281 301 | 32 510 539 |
2021-06-08 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −5 660 | 505 922 | −1,11 | 64,35 | −364 198 | 32 554 057 |
2021-05-06 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −445 | 511 582 | −0,09 | 57,39 | −25 539 | 29 359 691 |
2021-05-06 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −3 557 | 512 027 | −0,69 | 55,92 | −198 890 | 28 629 990 |
2021-05-06 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −5 998 | 515 584 | −1,15 | 55,09 | −330 436 | 28 404 038 |
2021-04-06 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −700 | 521 582 | −0,13 | 57,44 | −40 206 | 29 958 105 |
2021-04-06 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −4 156 | 522 282 | −0,79 | 56,46 | −234 669 | 29 490 653 |
2021-04-06 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −5 144 | 526 438 | −0,97 | 55,60 | −286 027 | 29 272 059 |
2021-03-04 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −1 878 | 531 582 | −0,35 | 61,58 | −115 647 | 32 734 820 |
2021-03-04 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −8 122 | 533 460 | −1,50 | 60,89 | −494 524 | 32 480 779 |
2021-02-16 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | −433 | 541 582 | −0,08 | 71,41 | −30 920 | 38 673 287 | |
2021-02-16 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | −2 614 | 542 015 | −0,48 | 70,17 | −183 422 | 38 032 651 | |
2021-02-11 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | −206 | 537 344 | −0,04 | 75,68 | −15 591 | 40 668 343 | |
2021-02-11 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | −1 262 | 537 550 | −0,23 | 74,66 | −94 218 | 40 132 408 | |
2021-02-11 |
|
4 | DNLI |
Denali Therapeutics Inc.
Restricted Stock Units |
M - Exercise | −4 250 | 8 500 | −33,33 | ||||
2021-02-11 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
M - Exercise | 4 250 | 538 812 | 0,80 | ||||
2021-02-05 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −1 912 | 534 562 | −0,36 | 68,61 | −131 180 | 36 675 764 |
2021-02-05 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −6 509 | 536 474 | −1,20 | 67,90 | −441 942 | 36 424 975 |
2021-02-05 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −1 579 | 542 983 | −0,29 | 66,65 | −105 239 | 36 189 274 |
2021-01-06 |
|
4 | DNLI |
Denali Therapeutics Inc.
Stock Option (right to buy) |
A - Award | 90 000 | 90 000 | |||||
2021-01-06 |
|
4 | DNLI |
Denali Therapeutics Inc.
Restricted Stock Units |
A - Award | 30 000 | 30 000 | |||||
2021-01-06 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −1 226 | 544 562 | −0,22 | 84,17 | −103 190 | 45 834 912 |
2021-01-06 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −1 900 | 545 788 | −0,35 | 82,96 | −157 631 | 45 280 646 |
2021-01-06 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −7 996 | 547 688 | −1,44 | 82,14 | −656 767 | 44 985 449 |
2021-01-06 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −2 817 | 555 684 | −0,50 | 81,45 | −229 433 | 45 258 072 |
2021-01-06 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −3 598 | 558 501 | −0,64 | 79,78 | −287 062 | 44 559 388 |
2021-01-06 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −7 876 | 562 099 | −1,38 | 78,42 | −617 675 | 44 082 614 |
2021-01-06 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −1 472 | 569 975 | −0,26 | 77,64 | −114 287 | 44 253 201 |
2021-01-06 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −980 | 571 447 | −0,17 | 76,41 | −74 877 | 43 661 579 |
2021-01-06 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −700 | 572 427 | −0,12 | 75,61 | −52 924 | 43 278 744 |
2021-01-06 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −5 144 | 573 127 | −0,89 | 74,01 | −380 698 | 42 416 098 |
2021-01-06 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −4 626 | 578 271 | −0,79 | 73,09 | −338 101 | 42 264 208 |
2021-01-06 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −8 531 | 582 897 | −1,44 | 72,22 | −616 094 | 42 095 830 |
2021-01-06 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −9 709 | 591 428 | −1,62 | 71,03 | −689 652 | 42 010 432 |
2021-01-06 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −9 340 | 601 137 | −1,53 | 70,10 | −654 738 | 42 139 944 |
2021-01-06 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −1 067 | 610 477 | −0,17 | 69,07 | −73 701 | 42 167 600 |
2021-01-06 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −518 | 611 544 | −0,08 | 67,78 | −35 110 | 41 449 841 |
2021-01-06 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −1 100 | 612 062 | −0,18 | 66,58 | −73 234 | 40 748 885 |
2021-01-06 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −1 400 | 613 162 | −0,23 | 65,17 | −91 233 | 39 957 560 |
2020-11-30 |
|
4/A | DNLI |
Denali Therapeutics Inc.
Common Stock |
F - Taxes | −1 954 | 614 562 | −0,32 | 32,88 | −64 248 | 20 206 799 | |
2020-11-30 |
|
4/A | DNLI |
Denali Therapeutics Inc.
Common Stock |
M - Exercise | 5 643 | 616 516 | 0,92 | ||||
2020-08-24 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
F - Taxes | −1 954 | 614 562 | −0,32 | 32,88 | −64 248 | 20 206 799 | |
2020-08-24 |
|
4 | DNLI |
Denali Therapeutics Inc.
Restricted Stock Units |
M - Exercise | −5 643 | 0 | −100,00 | ||||
2020-08-24 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
M - Exercise | 5 643 | 616 516 | 0,92 | ||||
2020-08-20 |
|
4 | DNLI |
Denali Therapeutics Inc.
Restricted Stock Units |
A - Award | 20 000 | 20 000 | |||||
2020-04-01 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | −1 427 | 28 662 | −4,74 | 19,49 | −27 812 | 558 622 | |
2020-04-01 |
|
4/A | DNLI |
Denali Therapeutics Inc.
Restricted Stock Units |
M - Exercise | −4 250 | 12 750 | −25,00 | ||||
2020-04-01 |
|
4/A | DNLI |
Denali Therapeutics Inc.
Common Stock |
M - Exercise | 4 250 | 30 089 | 16,45 | ||||
2020-02-12 |
|
4 | DNLI |
Denali Therapeutics Inc.
Stock Option (right to buy) |
A - Award | 136 000 | 136 000 | |||||
2020-02-12 |
|
4 | DNLI |
Denali Therapeutics Inc.
Restricted Stock Units |
A - Award | 29 143 | 29 143 | |||||
2019-12-05 |
|
4 | DNLI |
Denali Therapeutics Inc.
Stock Option (right to buy) |
M - Exercise | −3 121 | 108 937 | −2,79 | ||||
2019-12-05 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −3 121 | 25 839 | −10,78 | 18,00 | −56 178 | 465 102 |
2019-12-05 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
M - Exercise | 3 121 | 28 960 | 12,08 | 5,28 | 16 479 | 152 909 | |
2019-12-05 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −2 656 | 580 710 | −0,46 | 18,00 | −47 808 | 10 452 780 |
2019-12-05 |
|
4 | DNLI |
Denali Therapeutics Inc.
Stock Option (right to buy) |
M - Exercise | −711 | 112 058 | −0,63 | ||||
2019-12-05 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −711 | 25 839 | −2,68 | 18,01 | −12 805 | 465 360 |
2019-12-05 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
M - Exercise | 711 | 26 550 | 2,75 | 5,28 | 3 754 | 140 184 | |
2019-12-05 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −1 012 | 583 366 | −0,17 | 18,01 | −18 226 | 10 506 422 |
2019-11-26 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −229 | 584 378 | −0,04 | 18,02 | −4 127 | 10 530 492 |
2019-11-26 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −14 125 | 584 607 | −2,36 | 18,02 | −254 532 | 10 534 618 |
2019-11-26 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −646 | 598 732 | −0,11 | 18,00 | −11 628 | 10 777 176 |
2019-10-25 |
|
4 | DNLI |
Denali Therapeutics Inc.
Stock Option (right to buy) |
M - Exercise | −5 129 | 112 769 | −4,35 | ||||
2019-10-25 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
M - Exercise | 5 129 | 25 839 | 24,77 | 5,28 | 27 081 | 136 430 | |
2019-09-11 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −7 500 | 610 089 | −1,21 | 18,16 | −136 200 | 11 079 216 |
2019-08-22 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
F - Taxes | −1 975 | 20 710 | −8,71 | 18,60 | −36 731 | 385 160 | |
2019-08-22 |
|
4 | DNLI |
Denali Therapeutics Inc.
Restricted Stock Units |
M - Exercise | −5 643 | 5 643 | −50,00 | ||||
2019-08-22 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
M - Exercise | 5 643 | 22 685 | 33,11 | ||||
2019-08-09 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −7 500 | 617 589 | −1,20 | 18,81 | −141 075 | 11 616 849 |
2019-07-10 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −400 | 625 089 | −0,06 | 20,90 | −8 360 | 13 064 360 |
2019-07-10 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −7 100 | 625 489 | −1,12 | 20,25 | −143 775 | 12 666 152 |
2019-06-12 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −7 500 | 632 589 | −1,17 | 18,77 | −140 775 | 11 873 696 |
2019-05-13 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −2 500 | 640 089 | −0,39 | 21,09 | −52 725 | 13 499 477 |
2019-05-13 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −2 500 | 642 589 | −0,39 | 22,19 | −55 475 | 14 259 050 |
2019-05-13 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −2 500 | 645 089 | −0,39 | 22,86 | −57 150 | 14 746 735 |
2019-04-11 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −2 512 | 647 589 | −0,39 | 27,73 | −69 658 | 17 957 643 |
2019-04-11 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −2 513 | 650 101 | −0,39 | 28,26 | −71 017 | 18 371 854 |
2019-04-11 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −2 475 | 652 614 | −0,38 | 28,17 | −69 721 | 18 384 136 |
2019-03-13 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −1 512 | 655 089 | −0,23 | 24,33 | −36 787 | 15 938 315 |
2019-03-13 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −1 000 | 656 601 | −0,15 | 23,60 | −23 600 | 15 495 784 |
2019-03-13 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −2 513 | 657 601 | −0,38 | 22,40 | −56 291 | 14 730 262 |
2019-03-13 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −275 | 660 114 | −0,04 | 21,80 | −5 995 | 14 390 485 |
2019-03-13 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −2 200 | 660 389 | −0,33 | 21,20 | −46 640 | 14 000 247 |
2019-02-12 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −1 700 | 662 589 | −0,26 | 20,24 | −34 408 | 13 410 801 |
2019-02-12 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −800 | 664 289 | −0,12 | 19,73 | −15 784 | 13 106 422 |
2019-02-12 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −1 266 | 665 089 | −0,19 | 19,35 | −24 497 | 12 869 472 |
2019-02-12 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −1 234 | 666 355 | −0,18 | 18,74 | −23 125 | 12 487 493 |
2019-02-12 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −2 500 | 667 589 | −0,37 | 18,11 | −45 275 | 12 090 037 |
2019-02-11 |
|
4 | DNLI |
Denali Therapeutics Inc.
Stock Option (right to buy) |
A - Award | 136 000 | 136 000 | |||||
2019-02-11 |
|
4 | DNLI |
Denali Therapeutics Inc.
Restricted Stock Units |
A - Award | 17 000 | 17 000 | |||||
2019-01-11 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −2 500 | 670 089 | −0,37 | 20,80 | −52 000 | 13 937 851 |
2019-01-11 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −2 500 | 672 589 | −0,37 | 19,99 | −49 975 | 13 445 054 |
2019-01-11 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −2 500 | 675 089 | −0,37 | 20,31 | −50 775 | 13 711 058 |
2018-12-12 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −2 500 | 677 589 | −0,37 | 20,80 | −52 000 | 14 093 851 |
2018-12-12 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −2 500 | 680 089 | −0,37 | 20,22 | −50 550 | 13 751 400 |
2018-12-12 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
S - Sale | X | −2 500 | 682 589 | −0,36 | 20,18 | −50 450 | 13 774 646 |
2018-10-03 |
|
4 | DNLI |
Denali Therapeutics Inc.
Stock Option (right to buy) |
M - Exercise | −5 859 | 56 641 | −9,37 | ||||
2018-10-03 |
|
4 | DNLI |
Denali Therapeutics Inc.
Stock Option (right to buy) |
M - Exercise | −1 184 | 117 898 | −0,99 | ||||
2018-10-03 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
M - Exercise | 5 859 | 12 961 | 82,50 | 9,60 | 56 246 | 124 426 | |
2018-10-03 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
M - Exercise | 1 184 | 7 102 | 20,01 | 5,28 | 6 252 | 37 499 | |
2018-08-22 |
|
4 | DNLI |
Denali Therapeutics Inc.
Restricted Stock Units |
A - Award | 11 286 | 11 286 | |||||
2018-06-26 |
|
4 | DNLI |
Denali Therapeutics Inc.
Stock Option (right to buy) |
M - Exercise | −5 918 | 119 082 | −4,73 | ||||
2018-06-26 |
|
4 | DNLI |
Denali Therapeutics Inc.
Common Stock |
M - Exercise | 5 918 | 5 918 | 5,28 | 31 247 | 31 247 | ||
2018-02-28 |
|
4 | DNLI |
Denali Therapeutics Inc.
Stock Option (right to buy) |
A - Award | 180 000 | 180 000 | |||||
2017-12-07 | 3 | DNLI |
Denali Therapeutics Inc.
Common Stock |
1 370 178 | ||||||||
2017-12-07 | 3 | DNLI |
Denali Therapeutics Inc.
Common Stock |
1 370 178 |